Demethylcitalopram

Demethylcitalopram, also known as desmethylcitalopram or DCIT, is a primary active metabolite of the antidepressant citalopram. It is formed in the body through the demethylation of citalopram, a process primarily carried out by cytochrome P450 enzymes in the liver, particularly CYP2C19, CYP2D6, and CYP3A4. Demethylcitalopram exhibits pharmacological activity similar to its parent compound, acting as a selective serotonin reuptake inhibitor (SSRI). It binds to and inhibits the serotonin transporter (SERT), thereby increasing the extracellular concentration of serotonin in the synaptic cleft. This increased availability of serotonin is believed to contribute to the antidepressant effects of citalopram. While citalopram itself is a prodrug, demethylcitalopram is considered the main pharmacologically active component responsible for the therapeutic outcome. Individual differences in the activity of the cytochrome P450 enzymes can lead to variations in the metabolism of citalopram and the subsequent levels of demethylcitalopram, potentially influencing treatment response and side effect profiles. Research has explored demethylcitalopram's own pharmacokinetic and pharmacodynamic properties, and it is sometimes studied in its own right to understand the mechanisms of SSRIs more fully.